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AbstrACt
Introduction Emergency workers dedicate their lives 
to promoting public health and safety, yet suffer higher 
rates of post-traumatic stress disorder (PTSD) and major 
depression (MD) compared with the general population. 
They also suffer an associated increased risk for physical 
health problems, which may be linked to specific 
immunological and endocrine markers or changes in 
relevant markers. Poor physical and mental health is 
costly to organisations, the National Health Service 
and society. Existing interventions aimed at reducing 
risk of mental ill health in this population are not very 
successful. More effective preventative interventions 
are urgently needed. We first conducted a large-scale 
prospective study of newly recruited student paramedics, 
identifying two cognitive factors (rumination and resilience 
appraisals) that predicted episodes of PTSD and MD over 
a 2-year period. We then developed internet-delivered 
cognitive training for resilience (iCT-R), a supported online 
intervention, to modify cognitive predictors. This protocol is 
for a randomised controlled trial to evaluate the efficacy of 
the resilience intervention.
Methods and analysis 570 student paramedics will 
be recruited from participating universities. They will 
be randomly allocated to iCT-R or to supported online 
training of an alternative, widely available intervention 
or to training-as-usual. Follow-up will occur after the 
intervention/standard practice period and at 6, 12 and 
24 months. Primary outcomes include rates of PTSD and 
MD and subsydnromal PTSD and MD, measured by the 
Structured Clinical Interview for Diagnostic and Statistical 
Manual of Mental Disorders, fifth edition, the Patient-
Health Questionnaire-9 and the Post-traumatic Stress 
Disorder Checklist for Diagnostic and Statistical Manual 
of Mental Disorders, fifth edition. Secondary outcomes 
include measures of resilience, rumination, anxiety, 
psychological distress, well-being, salivary cortisol, plasma 
levels of C-reactive protein, smoking and alcohol use, 
weight gain, sleep problems, health-related quality of life, 
health resource utilisation and productivity.
Ethics and dissemination The Medical Sciences Inter-
Divisional Research Ethics Committee at the University 
of Oxford granted approval, reference: R44116/RE001. 
The results will be published in a peer-reviewed journal. 
Access to raw data and participant information will be 
available only to members of the research team.
trial registration number ISRCTN16493616; Pre-results.
IntroduCtIon  
Emergency workers carry a threefold increase, 
compared with the general population, in 
risk for major depression (MD) and post-trau-
matic stress disorder (PTSD) and an associ-
ated increased risk of poor physical health.1 
To date, interventions aimed at reducing risk 
of ill mental health in this population have 
been unsuccessful. Randomised controlled 
trials (RCT) found that trauma risk manage-
ment, a peer support system widely available 
strengths and limitations of this study
 ► The study is a large, single-blind randomised con-
trolled trial of internet-delivered cognitive training 
for resilience (iCT-R).
 ► iCT-R will be evaluated in comparison to an existing 
intervention and treatment as usual.
 ► Primary outcomes will be assessed by self-report 
and structured interviews.
 ► Full outcome blinding is not possible.
 ► Smoking and alcohol use will be measured with un-
published self-report tools.
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to the police and ambulance services in England2; critical 
incident stress debriefing widely used by UK fire-services,3 
and the charity Mind’s six-session group-based resilience 
intervention had no effect on resilience or rates of mental 
ill health.4 More effective preventative interventions for 
emergency workers are urgently needed.
Established interventions may have been unsuccessful 
because they fail to target predictors of mental ill health 
and are offered to emergency workers after rather than 
before repeated exposure to the stresses linked to their 
work. Moreover, cognitive strategies that could help them 
cope with characteristic stressors are not included as part 
of the training. For example, our and others’ research 
has demonstrated that exposure to trauma or stressful 
scenarios through imagery reduces anxiety for police 
officers and other at risk populations.5 6 Development 
of more effective interventions requires identification of 
predictors of mental disorders and an understanding of 
how to modify them.
In a series of experimental and prospective studies, we 
identified two cognitive factors that are robust predictors 
of poor mental health in emergency workers: rumination 
(repetitive negative thinking) and resilience appraisals. 
Those who reported ruminative thoughts during critical 
incidents were more likely to experience poor levels of 
coping.7 Adaptive appraisals during analogue trauma 
led to more successful attempts to regulate emotions 
and fewer PTSD symptoms.8 Our large-scale prospective 
study of newly recruited paramedics investigated predic-
tors of PTSD and MD derived from cognitive theories of 
PTSD and depression.1 Rumination at the start of para-
medic training uniquely predicted PTSD; low resilience 
uniquely predicted an episode of MD.
We then developed an intervention to modify peritrau-
matic ruminative thinking (ie, thinking repetitively in 
an abstract way during trauma). Training to think in a 
concrete style (eg, focusing on objective details and the 
sequence of events) led to significantly fewer intrusive 
memories and PTSD symptoms than individuals trained 
in a ruminative style.9 We also applied one of the core 
techniques of a successful treatment for PTSD (cogni-
tive therapy for PTSD10), updating the memory of the 
stressful event with helpful information, as a preventa-
tive strategy for dealing with analogue trauma and found 
that it is more helpful in reducing repetitive thinking and 
PTSD symptoms than control interventions including 
exposure.11
Research has further demonstrated that exposure to 
trauma or stressful scenarios through imagery reduces 
anxiety for police officers and other at risk populations, 
and that internet-based cognitive treatment that includes 
attention training as a core component significantly 
reduces anxiety.5 6 12
neurobiological factors linked to Ptsd and Md
Genetic and longitudinal studies suggest that inflamma-
tion is a pre-existing vulnerability factor for the develop-
ment of PTSD in trauma-exposed individuals rather than 
simply a correlate of subjective distress, disease severity or 
maladaptive coping strategies following PTSD onset.13 14 
For example, brain imaging studies have shown that high 
inflammation levels may increase threat perception 
(negative valence). Peripheral administration of lipopoly-
saccharides residues from bacterial cells’ components 
known to elicit a strong systemic inflammatory response, 
potentiates amygdala activity in response to socially threat-
ening stimuli (fear faces).15 In turn, greater pretreatment 
amygdala reactivity to threat predicts less symptom reduc-
tion during cognitive behaviour therapy.16 Additionally, 
inflammation is an important risk factor for depression 
and cardiovascular disease, which frequently accompany 
PTSD.17–19 Our study will investigate the link between 
inflammation and the development of PTSD and MD in 
trauma-exposed student paramedics. We will investigate 
whether or not internet cognitive training for resilience 
(iCT-R) can reduce levels of clinically relevant inflamma-
tion levels, such as C-reactive protein (CRP), known to 
increase risk of psychiatric as well as cardiovascular and 
metabolic conditions comorbid with PTSD and MD.
Given the wealth of literature supporting a relationship 
between the stress hormone, cortisol and PTSD and MD, 
we will also systematically assess the cortisol awakening 
response (CAR) and diurnal cycle. The CAR is an endo-
crine marker, defined as the change in cortisol concen-
tration that occurs during the first hour after waking 
from sleep.20 A meta-analysis of 62 studies concluded 
that increases in the CAR were associated with job stress 
and life stress and linked to greater fatigue, burnout and 
exhaustion and risk for later health states, such as coro-
nary heart disease.21 A recent study found that higher 
CAR predicted future episodes of MD within a 2.5-year 
period.20 We anticipate that iCT-R will reduce the CAR 
and cortisol throughout the day and protect against the 
development of PTSD and MD.
study objectives
The primary aim of the study is to evaluate the efficacy of 
iCT-R. We hypothesise that iCT-R will lead to fewer cases 
of PTSD and major depression (including subsyndromal 
PTSD and MD) and less severe PTSD and MD symptom-
atology at follow-up compared with an existing online 
training (Mind-Online) and standard practice.
secondary objectives
We hypothesise that iCT-R will lead to greater improve-
ment in secondary outcome measures (resilience, rumi-
nation, hormone and immune function, smoking, weight 
gain, alcohol use, symptoms of anxiety and sleep prob-
lems, psychological distress, well-being) than Mind-On-
line and standard practice. We also expect that iCT-R will 
be more cost-effective than Mind-Online and standard 
practice because of lower cost per participant without an 
episode or with low symptoms of PTSD or MD and lower 
costs per quality adjusted life years (QALY) gained for 
participants receiving iCT-R.
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tertiary objectives
We want to establish which baseline factors influence 
the effect of the interventions on primary and secondary 
outcomes so that we may make inferences about mech-
anisms of intervention efficacy. Understanding the 
effects that modifying risk and protective factors have 
may drive the refinement of future interventions. Our 
tertiary objectives are to determine which psychiatric, 
personality, trauma and social support factors at baseline 
(social support, trauma exposure, anxiety, age, gender, 
education, neuroticism, past and current psychiatric 
status, immune function) may influence (ie, moderate) 
the effect of the interventions on levels of symptoms 
(PTSD or MD), psychological distress and well-being at 
follow-up. Determining which factors moderate outcome 
may inform improvements to the intervention. For 
example, should baseline factors, such as education or 
age moderate outcome, then the intervention could be 
improved in light of relevant moderators. This could 
include making it more accessible to younger participants 
with less education should this be relevant, for example. 
We will also investigate whether or not changes in resil-
ience-related factors (rumination, responses to intru-
sions, concrete thinking, resilience appraisals, practice 
of iCT-R/Mind-Online tools) mediate symptom levels of 
PTSD and MD at 1-year and 2-year follow-up with iCT-R 
and Mind-Online. Finally, we will investigate whether or 
not concrete thinking, practice of tools and responses 
to intrusions at 6 months predict diagnoses and levels 
of PTSD and depression symptoms at 1-year and 2-year 
follow-up.
Methods
The protocol includes all details required for the WHO 
Trial Registration Data Set (online appendix 1) and was 
written in line with the Standard Protocol Items: Recom-
mendations for Interventional Trials statement, which 
outlines recommendations for a minimum set of scien-
tific, ethical and administrative elements that should be 
addressed in a clinical trial (online appendix 2).22
design
The proposed study is a single-blind (assessors blinded) 
randomised controlled trial in which n=570 student para-
medics will be randomly allocated to receive iCT-R, an 
already available intervention (Mind-Online) that has 
been investigated in previous trials or standard prac-
tice. Participants are also invited to give salivary and 
plasma samples before and after the interventions and 
at 1-year and 2-year follow-up. The trial will take place 
from October 2017 to January 2021.
Participants
Student paramedics will be recruited from collaborating 
paramedic training programmes (University of Brighton, 
Oxford Brookes University, Bournemouth University, 
University of Hertfordshire, University of Worcester, 
University of Surrey and Anglia Ruskin University). The 
locations selected constitute rural and city locations to 
improve generalisability. The researchers will present 
the study to each year group at collaborating universi-
ties to ensure the maximum reach of recruitment. After 
presenting the study, researchers will collect names and 
email addresses of interested students and email the 
registration survey including the participant information 
sheet (online appendix 3).
Inclusion and exclusion criteria
Students who are aged 18 and above, are training to be 
paramedics and are in years 1, 2 or 3 of their paramedic 
training programme will be eligible for the study. They 
will be screened for levels of PTSD and MD, and a trained 
research assistant will contact participants if they score in 
the clinical range on measures of PTSD or MD, or report 
suicidal ideation to evaluate whether they are eligible or 
need treatment (under JW’s supervision). The screening 
survey will trigger automatic notifications to the research 
assistant and the principal investigator if a participant 
scores 10 or above on the Patient Health Questionnaire 9 
(PHQ-9)23 or 1 or above on the suicidal ideation item of 
the same questionnaire or 33 or above on the Post-trau-
matic Stress Disorder Checklist for Diagnostic and Statis-
tical Manual of Mental Disorders, fifth edition (PCL-5).24 
Participants will be excluded from the study if their 
symptoms are interfering with their lives and they would 
like treatment, and the research assistant will offer them 
information on how to access evidence-based treatment 
for these conditions in local services.
sample size calculation
The risk of student paramedics developing full syndromal 
PTSD and MD over 2 years without intervention is 10%, 
and 25% if subsyndromal PTSD and MD are included.1 
Since there are no interventions for emergency workers 
which target modifiable risk factors, we referred to a study 
with a similar approach to facilitate the calculation of 
power. Topper et al evaluated the effects of an intervention 
targeting rumination on rates of depression in adolescents 
at 1-year follow-up in comparison to a waitlist condition.25 
The intervention reduced the rates of depression by 67% 
in comparison to the wait list condition. We estimated that 
our intervention, which also aims to modify rumination, 
would reduce rates of PTSD and depression by 50% in 
comparison to an existing intervention which has shown 
no change in rates of PTSD or MD over time.4 Setting 
power at 80%, α=0.05 and hypothesising a reduction of 
relative risk of 50% gives an OR of 0.429, which requires 
a total sample size of n=304 to show a risk reduction of 
50% between iCT-R and the alternative intervention. 
Thus, each condition would require n=152. Since we have 
a third condition (standard practice), the total sample size 
required would be n=456. Allowing for a 20% rate of attri-
tion, we will require a total sample size of n=570.
randomisation and blinding
Participants will be randomised on a 1:1:1 ratio as per a 
computer-generated randomisation schedule stratified 
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by site, gender and baseline PHQ-9 score (≥9 vs <9) 
and PCL-5 score (≥33 vs <33). The Oxford Clinical 
Trials Research Unit is independent to the research 
team and developed the randomisation programme. 
The researchers will inform participants of the inter-
vention they are to receive after they have completed 
baseline assessments. Outcome assessment will be single 
blind; questionnaires are completed online without any 
involvement of the researchers, the clinical interview 
will be conducted by an independent assessor blind 
to treatment allocation, and all personnel involved in 
processing and assessing the blood and saliva samples 
will be blinded to treatment allocation. Due to the nature 
of the interventions, participants cannot be completely 
blinded to allocation.
However, the inclusion of an already available, alterna-
tive intervention aims to mitigate some risk of bias.
Intervention arms
iCT-R aims to modify rumination and appraisals linked 
to low resilience in a six-session supported online inter-
vention. We include an imagery component, practice of 
strategies that has been shown to prevent stress-related 
responses from developing,8 9 attention training12 and 
monthly top-up exercises during follow-up to consoli-
date training, an approach that is lacking with existing 
interventions.
Our intervention follows a similar format to the inter-
net-based programmes that Clark, Ehlers, Wild and 
colleagues have developed for social anxiety and PTSD.12 26 
The core information is delivered in six modules. The 
modules include whiteboard videos to explain concepts, 
audio files for practising concrete thinking, testimo-
nies from qualified paramedics and video footage of 
student paramedic call-outs for use in experiential exer-
cises. Following our findings of the protective benefits 
of concrete thinking8 and the wealth of work in this 
area,(ie,27) participants are regularly reminded to prac-
tise concrete thinking.
The modules are:
1. It Matters What you Focus On: Helpful and Unhelpful 
Attention.
2. Get Out of Your Head with Helpful Thinking.
3. Habits and Dwelling: How to Change Them.
4. Dealing with Unwanted Memories: Then versus Now.
5. Transforming Worries and Improving Performance.
6. Beating Stress and Trauma: My Blueprint.
A trained online coach (research assistant) provides 
email feedback on students’ responses and, through 
an automated SMS programme, sends regular brief 
reminders of key points and notifications to practice 
IF-THEN plans (a technique shown to help individuals 
respond to warning signs for stress and dwelling).
Mind-Online
The alternative intervention is a series of six modules 
available online covering information and advice about 
stress, sleep problems, anger, depression, PTSD and 
mindfulness. Participants will receive the same frequency, 
type and duration of remote support as in iCT-R.
Standard practice
The third condition is training as usual. Participants will 
have access to the usual support offered through their 
university but they will not receive any online modules or 
remote support. They will be offered the iCT-R at the end 
of follow-up, when the study is completed.
Primary outcome measures
Levels of PTSD and MD
An independent assessor will administer the PTSD and 
MD modules of the Structured Clinical Interview for 
DSM-5 (SCID-5) to assess clinical and subsyndromal 
PTSD and MD.28 The SCID-5 is an interview schedule 
for determining DSM-5 psychiatric diagnoses. PTSD and 
MD symptomatology will also be assessed with contin-
uous measures: the PCL-5 and the PHQ-9,23 24 which will 
be completed at screening, which is typically the same 
day or shortly before the baseline questionnaires are 
released and completed. The PHQ-9 and PCL-5 scores at 
screening will be used as baseline scores in analyses. The 
PCL-5 is a self-report measure consisting of 20 questions 
that parallel the diagnostic criteria for PTSD set out in the 
Diagnostic and Statistical Manual of Mental Disorders, 
fifth edition.29
Items are scored on a five-point Likert scale (0=not at 
all’ to 4=‘extremely’). The PHQ-9 is a well-validated nine-
item self-report measure that assesses symptoms of depres-
sion. Items are scored on a four-point Likert scale (0=‘not 
at all’ to 3=‘nearly every day’). See table 1 for the full list 
of outcomes, measures and assessment time points.
secondary outcomes
Psychological outcomes
Two measures of resilience will be administered: the 
Wagnild Resilience Scale and the Connor-Davidson Resil-
ience Questionnaire (CD-RISC).30 31 Two measures of 
resilience will be used since it is unclear which one most 
sensitively measures resilience in student paramedics. The 
Wagnild Resilience Scale is a 25-item scale that measures 
resilience by rating responses to statements on a seven-
point Likert scale (0=‘strongly disagree’ to 7=‘strongly 
agree’). The CD-RISC is a commonly used self-report 
measure of resilience with 25 items scored on a five-point 
Likert scale (0 = ‘not true at all’ to 4 = ‘true nearly all the 
time’). Both scales are well-validated measures with excel-
lent psychometric properties. Rumination will be assessed 
with the brooding subscale of the Ruminative Responses 
Scale, a reliable and valid measure of the frequency of 
engaging in dwelling.32 Rumination in response to 
unwanted memories will be assessed with the dwelling 
subscale of the Responses to Intrusions Questionnaire, a 
reliable and valid measure of maladaptive responses to 
intrusive memories.33 Anxiety will be measured with the 
Generalised Anxiety Disorder scale 7, a seven-item scale 
with items scored on a four-point Likert scale (0=‘not at 
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all’ to 3= nearly every day’).34 Psychological distress will 
be measured with the reliable and valid 12-item General 
Health Questionnaire 12.35 Well-being will be assessed 
using the Warwick Edinburgh Mental Well-being Scale 
(WEMWBS).36 The WEMWBS has 14 items and is scored 
on a five-point Likert scale (1=‘none of the time’ to 5=‘all 
of the time’).
Hormone and immune function
Salivary cortisol will be assessed by radioimmunoassay 
(RIA) analysis. A sample of saliva will be collected on 
awakening, 15, 30 and 60 min after awakening and at 
12:00 and 20:00. Baseline high-sensitive CRP plasma levels 
will be measured using an ILab 600 spectrophotometric 
method in serum samples.
Health outcomes
Smoking and alcohol use will be measured with unpub-
lished questionnaires since two of our assessment points 
(1-year and 2-year follow-up) require participants to 
report current use as well as changes in alcohol use 
and smoking over the previous year, a time period not 
currently referenced in validated tools. Shorter ques-
tionnaires may reduce response burden and improve 
questionnaire completion. Participants will be asked 
to indicate whether or not they smoke, how many ciga-
rettes they smoke a day and whether this has increased, 
decreased or stayed the same in the last year. They will 
also be asked how many units of alcohol they have had 
in the last week, whether this is an average amount for 
them, and if not, how many units they usually drink per 
Table 1 Outcomes and measures
Domain Measures Time point*
Primary outcomes
  PTSD Structured Clinical Interview for Diagnostic and Statistical Manual of 
Mental Disorders, fifth edition Disorders (SCID-5)28 Post-traumatic 
Stress Disorder Checklist for DSM-524
0 1 3 4
0 1 2 3 4
  MD SCID-5.28 Patient Health Questionnaire 923 0 1 3 4
0 1 2 3 4
Secondary outcomes
  Resilience Connor-Davidson Resilience Questionnaire31
Wagnild Resilience Scale30
0 1 3 4
0 1 3 4
  Rumination Ruminative Responses Scale brooding subscale32
Responses to Intrusions Questionnaire dwelling subscale33
0 1 3 4
  Anxiety Generalised Anxiety Disorder seven-item scale34 0 1 3 4
  Smoking and Alcohol use Smoking Behaviour Questionnaire.1 Alcohol Use Questionnaire1 0 1 3 4
  Weight and Height Questionnaire recording participants’ height and weight1 0 1 3 4
  Psychological distress General Health Questionnaire35 0 1 3 4
  Well-being Warwick Edinburgh Mental Well-being Scale36 0 1 3 4
  Hormone function Level of cortisol in response to awakening and throughout the day 0 1 3 4
  Immune function Level of C-reactive protein 0 1 3 4
  Sleep problems Insomnia Severity Index37 0 1 3 4
  Health economics EuroQol 5 Dimensions Questionnaire38 0 1 3 4 
Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric 
Illness41
0 1 3 4 
Client Service Receipt Inventory39 0 1 3 4 
Health and Labour Questionnaire40 0 1 3 4
Tertiary outcomes
  Neuroticism Eysenck Personality Questionnaire neuroticism subscale42 0 1 3 4
  Social support Social Support scale adapted from a brief measure of social support43 0 1 3 4
  Demographics General information questionnaire1 0 3 4
  Trauma exposure Trauma screener44 0 1 2 3 4
  Concrete thinking Concrete thinking questionnaire, adapted from a previous concrete 
thinking assessment43
0 1 2 3 4
  Intrusions Duration, frequency and distress linked to Intrusions Questionnaire44 0 1 2 3 4
*Time point: 0=baseline, 1=postintervention, 2=6-month follow-up, 3=12-month follow-up, 4=24-month follow-up.
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week. Weight gain will be measured by increases in body 
mass index. Participants will be asked to provide their 
weight and height. The researchers will take weighing 
scales and a tape measure to study visits to weigh and 
measure participants. Sleep problems will be assessed by 
the Insomnia Severity Index, which is a reliable and valid 
brief self-report instrument of sleep quality and sleep 
difficulties.37 In line with National Institute for Health 
and Care Excellence guidelines, health related quality 
of life will be measured by the five-levels version of the 
EuroQol 5 Dimensions questionnaire (EQ-5D-5L).38 The 
EQ-5D-5L is a validated and widely used generic measure-
ment of health related quality of life based on five dimen-
sions: mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression. Although, we do not expect that 
all five dimensions will be affected by the intervention, we 
need to collect data on all dimensions in order to deter-
mine quality adjusted life years (QALYs).
Costs
The economic evaluation will be conducted by taking the 
National Health Service (NHS) perspective (including 
the costs of using mental health services) and the broader 
societal perspective (including the costs of productivity 
loss due to illness). Mental health resource utilisation 
will be measured with an adapted version of the Clinical 
Service Receipt Inventory and valued by using published 
unit costs (eg, NHS Reference Costs and Unit Costs 
of Health and Social Care).39 Productivity loss will be 
measured with Short Form-Health and Labour Question-
naire,40 a validated questionnaire part of the Trimbos/
iMTA questionnaire for Costs associated with Psychiatric 
Illness.41
tertiary outcomes
To assess potential moderators of outcomes, we will 
measure psychiatric, personality, trauma and social 
support factors at baseline (social support, trauma expo-
sure, anxiety, age, gender, education, neuroticism, past 
and current psychiatric status, immune function). The 
neuroticism subscale (12 items) of the Eysenck Person-
ality Questionnaire has excellent psychometric properties 
and is a measure of emotionality.42 We will use an adapted 
version of a brief measure of social support, to assess 
perceived support from and closeness to friends, family 
and work colleagues, as well as use of social support.43 
Trauma exposure will be measured using a 19-item 
unpublished trauma questionnaire relevant to emer-
gency workers, which includes items from the Life Events 
Checklist.44 We will also collect demographic information 
(age, gender, and level of education), information on 
the duration, frequency and distress linked to the Intru-
sions Questionnaire,45 and questions about concrete and 
abstract thinking based on an existing assessment tool.46 
Participants will be asked to think about a problem they 
are having and write questions that may go through 
their minds in relation to the problem. They will then be 
presented with four problem scenarios and asked to select 
from a list the likely thoughts they would have if faced 
with the problem. The list consists of a range of concrete 
and abstract thoughts. We will investigate whether or 
not changes in resilience-related factors (rumination, 
responses to intrusions, concrete thinking, resilience 
appraisals, practice of iCT-R/Mind-Online tools) mediate 
symptom levels of PTSD and MD at 1-year and 2-year 
follow-up with iCT-R and Mind-Online. We will also inves-
tigate whether or not concrete thinking, practice of tools 
and responses to intrusions at 6 months predict diagnoses 
and levels of PTSD and depression symptoms at 1-year 
and 2-year follow-up.
Patient and public involvement
We held three User Advisory Groups with student para-
medics who contributed to the design of the study, the 
selection of questionnaires and the content of the interven-
tion. The first User Advisory Group was co-organised with 
the Research Design Service South Central Patient and 
Public Involvement Officer, Megan Barlow Pay. Research 
questions and outcome measures were discussed with all 
feedback incorporated, including the development of a 
module participants requested to address socially anxious 
concerns common to their combined role as student and 
paramedic. A further two User Advisory Groups were held 
to review the intervention and to develop four versions of 
a questionnaire to assess concrete and abstract thinking 
in situations specific to student paramedics. Participants 
also completed the baseline questionnaires to assess their 
length of time and to provide feedback on the feasibility 
of administration. Participants were not involved in the 
recruitment and conduct of the study. Results will be 
made available in summary format to all participants by 
email once the study is completed.
Procedure
Researchers will present the study at collaborating univer-
sities and invite student paramedics to take part. Inter-
ested participants will be given a weblink to the study via 
our software platform, Qualtrics, where they can read and 
print a PDF copy of the Participant Information Sheet 
and discuss questions with the research assistant over the 
telephone. If they decide to take part, they will be emailed 
a link where they can login, re-read the Participant Infor-
mation Sheet and complete a consent form (see online 
appendix 3 for the Participant Information Sheet and 
Consent Form). Written consent will be requested from 
participants before blood and saliva samples are taken. It 
will be made clear that participation is entirely voluntary 
and that volunteers may withdraw from the study at any 
point without incurring any negative consequences.
Participants will be recruited over a 12-month period. 
They will complete online two questionnaires (PCL-5 and 
PHQ-9) to assess eligibility. If participants score≥10 on 
the PHQ-9, ≥33 on the PCL-5 or ≥1 on the PHQ-9 suicidal 
ideation item, a researcher will telephone the partici-
pant to determine symptom severity and whether treat-
ment is necessary. A risk assessment will be conducted 
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if a participant scores ≥1 on the PHQ-9 suicidal ideation 
item. If treatment is needed, participants will be sign-
posted to their GP and local psychological services. If 
participants are eligible and consent to participate in the 
study, they will be assigned a participant ID number to 
ensure anonymity is maintained. They will complete a 
set of questionnaires online, take part in a clinical inter-
view conducted by an independent assessor, and provide 
blood and saliva samples. The clinical interviews will be 
recorded on SanDisk MP3 recorders to ensure that the 
questions asked are standardised across all assessment 
interviews. Qualified phlebotomists will visit students at 
their universities to collect blood samples. During this 
study visit, participants will be provided with equipment 
to collect their saliva at home on awakening and through 
the day (six samples in total). Saliva and blood samples 
will be transported to the University of Surrey for assay 
analysis. The blood samples will be centrifuged immedi-
ately and only serum will be kept for analysis.
Once baseline assessments are completed, participants 
will be randomly allocated to iCT-R, Mind-Online or 
standard practice. When the interventions or standard 
practice are completed, participants will complete the 
full battery of assessments again; they will complete the 
questionnaires online, take part in a clinical interview, 
and provide blood and saliva samples. Six months later, 
they will complete online a shorter set of questionnaires. 
At 12-month and 24-month follow-up, they will complete 
the full battery of assessments again. See figure 1 for a 
timeline of the study including the enrolment process, 
randomisation, interventions and assessments. We are 
aware that there are various tasks to complete at each 
assessment point. This may be off-putting to participants 
and increase the likelihood of drop outs and respondent 
Figure 1 Study time line. The flow chart shows how participants will progress through the study from the initial stage of 
enrolment through to analysis. 
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fatigue. We will clearly communicate the value of the 
assessments being administered, and participants will be 
compensated with £30 and a certificate of completion at 
follow-up time points to discourage drop out. The reasons 
for non-adherence to the intervention or dropping out 
of the study will be recorded. An independent rater will 
assess treatment fidelity. The content of a random sample 
of email communications will be scored for reference to 
content relevant to each training programme.
data management
Registration and assessment data will be captured online 
via Qualtrics software. Participants will be assigned a 
unique code to be used for all data files and audio tapes. 
Access to the system will be restricted to named study 
personnel and via password protection. The University 
of Oxford’s IT services have arranged for the files to be 
encrypted and backed up on a weekly basis using a Tivoli 
Storage Manager (TSM). The data will be copied to three 
separate tapes; one copy will reside in the Tape Robot in 
the IT Services Machine room and the other two are held 
in locked fireproof safes, one on-site at IT services and 
one off-site in locked premises. The data on the tapes are 
inaccessible without the TSM database. The data on the 
off-site tapes are encrypted. Papers from clinical inter-
views will be kept in locked cabinets at the University of 
Oxford. The audiotapes from clinical interviews will be 
backed up online with password-protection and access 
restricted to study personnel. The blood samples will be 
centrifuged as soon as the laboratory at the University of 
Surrey receives them on the day of collection. The cellular 
component will be discarded and the serum will be stored 
at −80°C. Saliva samples will be analysed at the University 
of Surrey by RIA analysis to detect levels of cortisol.
In line with the Oxford Clinical Trials Research Unit 
and the Medicines for Human Use Clinical Trials Regu-
lations (2004), we have not recruited a Data Monitoring 
Committee because recruitment and follow-up occur over 
a short period, there are minimal risks to participants and 
the trial protocol will not be modified regardless of the 
interim data.
statistical analyses
In line with the BMJ and Consolidated Standards of 
Reporting Trials guidelines, data analysis will be intent-
to-treat. All participants who have been randomised will 
be included in analyses, including those who drop out. 
We will compare dichotomous measures (rates of PTSD 
and MD, changes in alcohol use and smoking) between 
conditions using Χ2 analysis. Continuous measures will 
be analysed using hierarchical linear modelling. This 
analysis models random slopes and intercepts for partic-
ipants and tests the fixed effects of repeated assessments 
over time (level 1, preintervention, postintervention, 
1 and 2 year follow-up) and training condition (level 2, 
iCT-R, Mind-Online, Standard Practice) using data from 
all participants. It takes into account that participants are 
nested within site (level 3). Variables will be centred for 
the analysis. The effects of potential moderators (social 
support, exposure to critical incidents, etc) on PTSD and 
depression symptoms will be explored by including main 
effects and interactions with treatment effects into the 
model. Non-significant moderators will be removed from 
the final model.
To address the potential for Type I error when evalu-
ating our secondary outcomes (ie, resilience, rumina-
tion, hormone and immune function, smoking, weight 
gain, alcohol use, anxiety, sleep problems, psychological 
distress, well-being), we will examine and report effect 
sizes. Effect sizes are a reliable method for determining 
the quality of the result that do not rely on p value signif-
icance and are not affected by the number of outcomes.
Mediation analyses will be conducted to assess whether 
or not changes in resilience-related factors (rumina-
tion, responses to intrusions, concrete thinking, resil-
ience appraisals, practice of iCT-R/Mind-Online tools) 
and compliance with the training programmes mediate 
symptom levels of PTSD and MD at one and 2 year 
follow-up with iCT-R and Mind-Online.
A trial-based economic evaluation will be conducted 
to investigate the cost-effectiveness of the intervention in 
terms of cost per QALY gained. Uncertainty in the results 
will be addressed in sensitivity analyses and displayed in 
cost-effectiveness planes and cost-effectiveness accept-
ability curves.
Adverse events
We do not anticipate any adverse events. However, it is 
possible that a participant may evidence risk at one of the 
assessment points (preintervention, postintervention or 
12 and 24 month follow-up). If this is the case, risk will 
be assessed over the telephone and the individual will be 
signposted to the appropriate service.
Should a serious adverse event (SAE) occur where, 
in the opinion of the principal investigator, the event 
was ‘related’ (resulted from administration of any of 
the research procedures) and ‘unexpected’ in relation 
to those procedures, it will be reported to the research 
ethics committee. Reports of related and unexpected 
SAEs will be submitted within 15 working days of the 
principal investigator becoming aware of the event, using 
the Health Research Authority safety report form for a 
non-Clinical Trial of an Investigation of a Medicinal 
Product (non-CTIMP).
The University of Oxford has a specialist insurance 
policy in place, which would operate in the event of any 
participant suffering harm as a result of their involvement 
in the research (Newline Underwriting Management Ltd, 
at Lloyd’s of London).
Ethics and dissemination
Ethical approval of the research protocol was gained from 
The Medical Sciences Inter-Divisional Research Ethics 
Committee at the University of Oxford, 17 August 2017, 
ref: R44116/RE001. This is protocol version 1. Any 
substantive amendments to the protocol will be conducted 
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by the principal investigator and reviewed by the research 
ethics committee.
The research results will be submitted for publication in 
a peer-reviewed journal and presented at relevant confer-
ences. Direct access to data will be granted to authorised 
representatives from the host institution and the regula-
tory authorities to permit trial-related monitoring, audits 
and inspections.
Committees
We have established a trial oversight committee (TOC). 
Our independent chairman is Dr Susan Dutton, the 
Senior Medical Statistician and Oxford Clinical Trials 
Research Unit Lead Statistician. The principal investi-
gator is also a member of the TOC and we have one lay 
qualified paramedic member (Graham Harris). The TOC 
will meet before the start of the trial and three more times 
before the end of the trial.
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